Projects to Support Renewable Energy Generation, Reduce Landfilling, and Deliver Environmental and Economic Benefits SCOTTSDALE, AZ / ACCESS Newswire / December 29, 2025 / Eco Innovation Group, Inc. (OTC:ECOX) ("ECOX" or the "Company") and WRA Holdings, Inc. ("WRA") announce continued progress in the development of a national conversion technology waste-to-energy ("WTE") initiative across Costa Rica. The initiative is designed to address long-term municipal and agricultural waste management needs while supp ...

Proceeds to Support the Company’s Assessment of Opportunities to Advance BX011 and Ongoing Evaluation of Strategic AlternativesNESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has entered into definitive agreements in connection with a private investment in public equity (“Private Placement”) financin ...

分析师背景与团队 - 分析师Scott Kaufman拥有超过十年的金融行业直接经验 [1] - 分析师Scott Kaufman是Dividend Kings的首席分析师 专注于提供高质量股息增长和价值被低估机会的可操作见解 [1] - 其投资重点在于获取丰厚的现金股息和强劲的资本利得 以实现稳健的总回报 [1] - Kody's Dividends, Justin Law, 和 Rachel Kaufman 是Dividend Kings团队的成员 [2] 信息披露与免责 - 分析师声明未持有任何提及公司的股票、期权或类似衍生品头寸 且在未来72小时内无建立此类头寸的计划 [2] - 文章内容代表分析师个人观点 且除来自Seeking Alpha的报酬外未获得其他补偿 [2] - 分析师与文章中提及的任何股票所属公司无业务关系 [2] - Seeking Alpha声明其并非持牌证券交易商、经纪商、美国投资顾问或投资银行 [2] - 其分析师为第三方作者 包括可能未经任何机构或监管机构许可或认证的专业投资者和个人投资者 [2]

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the "Company†) today announced the successful completion of its acquisition of Halda Therapeutics OpCo, Inc. ("Halda†), a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTACâ"¢) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash. "This strategic milestone underscores our commitment to redefining c ...

Every time Medicare open enrollment comes around, millions of older adults wrestle with the same annual dilemma: stick with their current plan or switch. Two influential voices — comedian John Oliver and personal finance expert Suze Orman — are making a forceful case for abandoning Medicare Advantage (MA). When high-profile figures offer such strong advice, it can be hard to ignore, even among the people who are satisfied with their MA plan. “If I’m satisfied with my Medicare Advantage plan, why are th ...

Apple has been lagging in the AI race compared to the other tech giants. While other tech giants have raced ahead with improved AI chatbots, video-generating apps, and much advanced AI models, Apple ... ...

The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in essential tremor Praxis remains on track to submit ulixacaltamide NDA in early 2026 based on recently completed pre-NDA meeting with the FDA BOSTON, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders chara ...

neffy is the first epinephrine product approved for use out of a hospital setting in China for adults and children (>30 kg) living with severe allergic reactions Pediatrix Therapeutics, which has a license from ARS Pharma to market neffy in China under the trade name 优敏速®, expects availability in the spring of 2026 SAN DIEGO, Dec. 29, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial-stage biopharmaceutical company dedicated to empowering at-risk patients and their caregivers t ...

PONTE VEDRA, FL / ACCESS Newswire / December 29, 2025 / Every industry has its forgotten corners. In anticoagulation, those corners turned into entire neighborhoods. ...

NEW YORK, Dec. 29, 2025 /PRNewswire/ -- IQSTEL Inc. (NASDAQ: IQST) ("IQSTEL" or the "Company") today issued a year-end shareholder recap highlighting a transformational 2025 marked by its successful NASDAQ uplisting, a revenue run rate of approximately $400 million, expanding profitability with a $2.7 million Adjusted EBITDA run rate, strategic growth in Fintech and Cybersecurity, and the announcement of the Company's first-ever shareholder dividend. The recap underscores IQSTEL's evolution into a diversifi ...